Shield Therapeutics (STX) 주식 개요
상업화 단계의 전문 제약 회사인 Shield Therapeutics plc는 미충족 의료 수요를 치료하기 위한 의약품 상용화에 주력하고 있습니다. 자세히 보기
STX Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Shield Therapeutics plc 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | UK£0.047 |
| 52주 최고가 | UK£0.13 |
| 52주 최저가 | UK£0.037 |
| 베타 | 1.77 |
| 1개월 변동 | 7.13% |
| 3개월 변동 | -27.19% |
| 1년 변동 | -48.22% |
| 3년 변동 | -53.98% |
| 5년 변동 | -88.56% |
| IPO 이후 변동 | -97.03% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • Jul 07
STX: Japan Trial Progress Will Drive Future Earnings Upside
Analysts have reduced their fair value estimate for Shield Therapeutics from £0.14 to £0.12, reflecting updated assumptions around revenue growth, profit margins, and a higher expected future P/E multiple. What’s in the News for Shield Therapeutics Shield Therapeutics reported that partner MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc., enrolled the first patient in a Phase II clinical trial in Japan for ACCRUFeR (ferric maltol) as a potential treatment for Pulmonary Arterial Hypertension, following confirmation of the development plan by Japan’s Pharmaceuticals and Medical Devices Agency, source: company announcement.
내러티브 업데이트 • Jun 23
STX: Pediatric And Pulmonary Hypertension Trials Will Support Future Upside
Analysts have trimmed their fair value estimate for Shield Therapeutics from £0.17 to £0.17 after updating their assumptions for revenue growth, profit margins and the future P/E multiple, resulting in a slightly lower price target. What's in the News for Shield Therapeutics Shield Therapeutics announced that partner MEDLEAP Pharma, a subsidiary of Vital KSK Holdings, has enrolled the first patient in a Phase II clinical trial in Japan evaluating ACCRUFeR (ferric maltol) for Pulmonary Arterial Hypertension, following prior confirmation of the development plan by Japan's Pharmaceuticals and Medical Devices Agency.내러티브 업데이트 • Jun 05
STX: Pediatric And Japan Trial Milestones Will Drive Future Earnings Upside
Shield Therapeutics' analyst price target is now set at £0.14. Analysts attribute this level to unchanged fair value, discount rate and P/E assumptions, combined with modest adjustments to revenue growth and profit margin forecasts.내러티브 업데이트 • May 21
STX: Pediatric And Asia Regulatory Milestones Will Drive Future Earnings Upside
Shield Therapeutics’ latest analyst price target has been set at £0.14, with analysts attributing this unchanged fair value to a slightly adjusted discount rate, modestly revised revenue growth and profit margin assumptions, and a recalibrated future P/E multiple. What's in the News MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc., enrolled the first patient in a Phase II exploratory clinical trial in Japan evaluating ACCRUFeR (ferric maltol) for Pulmonary Arterial Hypertension.내러티브 업데이트 • May 04
STX: Pediatric And Asia Expansion Will Drive Future Earnings Upside
Analysts have adjusted their price target on Shield Therapeutics to £0.14 per share, with the change linked to updated assumptions that maintain the fair value level while recalibrating revenue growth, profit margin and future P/E expectations. What's in the News Partner MEDLEAP Pharma enrolled the first patient in a Phase II clinical trial in Japan testing ACCRUFeR (ferric maltol) as a potential treatment for pulmonary arterial hypertension, following prior confirmation of the development plan by Japan's Pharmaceuticals and Medical Devices Agency (Product-Related Announcement).내러티브 업데이트 • Apr 18
STX: Expanded Pediatric Reach And China Entry Will Support Stronger Future Earnings
Analysts have trimmed their fair value estimate for Shield Therapeutics to £0.14 per share, citing updated assumptions that combine a lower revenue growth outlook with a higher projected profit margin and a reduced future P/E multiple. What's in the News EMA's Committee for Medicinal Products for Human Use issued a positive opinion to extend FeRACCRU's indication to include adolescents, so it is now indicated for iron deficiency in adults and pediatric patients 12 years and older in Europe, with all measures in the agreed Pediatric Investigation Plan confirmed as fulfilled (Key Developments).분석 기사 • Apr 12
Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17
It's been a good week for Shield Therapeutics plc ( LON:STX ) shareholders, because the company has just released its...내러티브 업데이트 • Apr 03
STX: Pediatric And China Approvals Will Expand Future Earnings Power
Analysts have maintained their fair value estimate for Shield Therapeutics at £0.14. The discount rate remains unchanged, and updated assumptions for revenue growth, profit margin and future P/E support the latest price target view.내러티브 업데이트 • Mar 20
STX: Pediatric Label Expansion And Added Exclusivity Will Support Future Upside
Analysts have kept their fair value framework for Shield Therapeutics broadly unchanged, with a slightly adjusted profit margin outlook and future P/E assumption. These updates feed into a refreshed price target in £ terms that remains closely aligned with the prior figure.내러티브 업데이트 • Mar 06
STX: Pediatric Expansion And China Filing Will Redefine Earnings Power
Analysts have lifted their price target for Shield Therapeutics to £0.14 from £0.10, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E that they view as better aligned with the company’s current outlook. What's in the News Shield Therapeutics filed and received acceptance of a Marketing Authorisation Application for ACCRUFeR with China’s National Medical Products Administration for adults with iron deficiency, supported by prior US FDA data and a Phase 3 study in Chinese adults with iron deficiency anemia and inflammatory bowel disease who are intolerant to oral ferrous products (Key Developments).내러티브 업데이트 • Feb 19
STX: Pediatric Expansion And Extended Exclusivity Will Support Future Upside Potential
Analysts have kept their fair value estimate for Shield Therapeutics broadly steady at £0.17 per share, reflecting only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that they see as refinements rather than a change in thesis. What's in the News The FDA approved an extension of the indication for ACCRUFeR (ferric maltol) to treat iron deficiency in adult and pediatric patients 10 years and older, following a priority review supported by a Phase 3 pediatric trial in children from 1 month of age with iron deficiency anemia (Key Developments).내러티브 업데이트 • Feb 05
STX: Expanded Pediatric Indications And New Market Approvals Will Drive Upside
Analysts have nudged their price target for Shield Therapeutics slightly higher, reflecting small adjustments to revenue growth, profit margin expectations, and the implied future P/E multiple. What's in the News Shield Therapeutics issued earnings guidance for 2026, indicating that it expects to deliver an operating profit in that year (company guidance).내러티브 업데이트 • Jan 22
STX: Pediatric Expansion And New Market Approvals Will Support Future Upside
Analysts have lifted their price target on Shield Therapeutics from £0.16 to about £0.17, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What’s in the News US FDA grants priority review approval to extend ACCRUFeR’s indication to adolescents, covering iron deficiency treatment in patients 10 years and older, backed by positive Phase 3 pediatric trial data (FORTIS/ST10-01-305) (Key Developments).내러티브 업데이트 • Jan 07
STX: Expanded Pediatric And Global Approvals Will Support Future Upside
Analysts have trimmed their price target on Shield Therapeutics slightly, citing updated expectations for revenue growth of about 41.81%, a lower projected profit margin of around 13.33% and a higher future P/E of roughly 17.49x. Together, these factors imply less upside potential from current levels in cash terms than previously estimated.내러티브 업데이트 • Dec 18
STX: Future US Label Expansion Could Still Leave Shares Vulnerable
Analysts have raised their price target for Shield Therapeutics from 0.03 dollars to 0.10 dollars, citing slightly stronger long term revenue growth expectations, while applying a higher discount rate and more conservative profit margin and valuation multiples. What's in the News Presentation of pediatric FORTIS PK sub study at the American Society of Hematology conference in December 2025 showed ferric maltol is well absorbed across pediatric age groups, with maltol rapidly metabolized and excreted, supporting its suitability for iron replacement in children and adolescents (company announcement).내러티브 업데이트 • Dec 04
STX: New Regulatory Approvals And Pediatric Data Will Drive Future Upside
Analysts have modestly increased their price target on Shield Therapeutics, citing slightly stronger projected revenue growth, a marginally lower profit margin, and a modestly higher future price-to-earnings multiple. What's in the News The Korean Ministry of Food and Drug Safety granted regulatory approval for ACCRUFeR (ferric maltol) in adults with iron deficiency, opening a new commercial market and triggering eligibility for milestones and royalties (company announcement).분석 기사 • Nov 25
Shield Therapeutics plc's (LON:STX) Subdued P/S Might Signal An Opportunity
With a median price-to-sales (or "P/S") ratio of close to 2.6x in the Pharmaceuticals industry in the United Kingdom...내러티브 업데이트 • Nov 20
STX: FDA Priority Review and Regulatory Approvals Will Drive Significant Upside
Analysts have modestly raised their price target for Shield Therapeutics from $0.16 to $0.16 per share. This change reflects updated assumptions around discount rates and profit margins, while maintaining a cautiously optimistic outlook.내러티브 업데이트 • Nov 06
STX: Upcoming FDA Decision Will Drive Confidence After Positive Pediatric Results
Analysts have maintained their price target for Shield Therapeutics at $0.16, citing stable projections in key financial metrics, including revenue growth and profit margin improvements, as justification for the unchanged valuation. What's in the News Positive efficacy, tolerability, and palatability results for the ferric maltol pediatric FORTIS clinical trial were presented at the American Association of Pediatrics National Conference.내러티브 업데이트 • Oct 22
Analysts Maintain Target for Shield Therapeutics Amid Positive Clinical News and Stable Valuation Metrics
Narrative Update on Shield Therapeutics: Analyst Price Target Revision Analysts have maintained their price target for Shield Therapeutics at £0.16. This reflects confidence in the company's prospects, given stable fair value estimates and consistent growth expectations.내러티브 업데이트 • Oct 08
Global Aging Trends And Early Detection Will Unlock Markets
Analysts have raised their price target on Shield Therapeutics from $0.14 to $0.16 per share, citing improved profit margin expectations and a steady long-term outlook, despite minor adjustments to growth forecasts. What's in the News Positive efficacy, tolerability, and palatability results for ferric maltol pediatric FORTIS clinical trial were presented at the AAP National Conference, showing significant hemoglobin improvements with no serious adverse events reported (Key Developments).분석 기사 • Aug 23
The Market Lifts Shield Therapeutics plc (LON:STX) Shares 76% But It Can Do More
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 76% in...새로운 내러티브 • Aug 03
Global Aging Trends And Early Detection Will Unlock Markets
An expanding addressable market and greater screening activity are driving strong prescription growth and recurring revenues for Shield's main product.분석 기사 • Jun 28
Shield Therapeutics plc (LON:STX) Soars 27% But It's A Story Of Risk Vs Reward
Shield Therapeutics plc ( LON:STX ) shares have had a really impressive month, gaining 27% after a shaky period...분석 기사 • Feb 06
Even With A 26% Surge, Cautious Investors Are Not Rewarding Shield Therapeutics plc's (LON:STX) Performance Completely
Shield Therapeutics plc ( LON:STX ) shareholders have had their patience rewarded with a 26% share price jump in the...분석 기사 • Oct 30
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Shield Therapeutics plc ( LON:STX ) share price has softened a substantial 28% over the previous 30 days, handing...분석 기사 • Oct 12
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Aug 01
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 44% in...분석 기사 • Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Key Insights Shield Therapeutics will host its Annual General Meeting on 20th of June CEO Greg Madison's total...분석 기사 • May 22
Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
Shield Therapeutics plc ( LON:STX ) shareholders are no doubt pleased to see that the share price has bounced 35% in...주주 수익률
| STX | GB Pharmaceuticals | GB 시장 | |
|---|---|---|---|
| 7D | -15.3% | -3.3% | -1.8% |
| 1Y | -48.2% | 2.1% | 15.2% |
수익률 대 산업: STX은 지난 1년 동안 2.1%의 수익을 기록한 UK Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: STX은 지난 1년 동안 15.2%를 기록한 UK 시장보다 저조한 성과를 냈습니다.
주가 변동성
| STX volatility | |
|---|---|
| STX Average Weekly Movement | 12.8% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.5% |
안정적인 주가: STX의 주가는 지난 3개월 동안 UK 시장보다 변동성이 컸습니다.
시간에 따른 변동성: STX의 주간 변동성(13%)은 지난 1년 동안 안정적이었지만 UK 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2008 | 61 | Karl Lundstrom | www.shieldtherapeutics.com |
상업화 단계의 전문 제약 회사인 Shield Therapeutics plc는 미충족 의료 수요를 치료하기 위한 의약품 상용화에 주력하고 있습니다. 주요 제품은 빈혈 유무에 관계없이 철분 결핍을 치료하는 성인용 무염 경구 치료제인 아크루퍼/페라크루입니다. 2008년 설립되었으며 영국 게이츠헤드에 본사를 두고 있습니다.
Shield Therapeutics plc 기초 지표 요약
| STX 기초 통계 | |
|---|---|
| 시가총액 | UK£49.86m |
| 순이익 (TTM) | -UK£7.67m |
| 매출 (TTM) | UK£43.34m |
1.2x
주가매출비율(P/S)-6.5x
주가수익비율(P/E)STX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| STX 손익계산서 (TTM) | |
|---|---|
| 매출 | US$58.63m |
| 매출원가 | US$28.06m |
| 총이익 | US$30.57m |
| 기타 비용 | US$40.94m |
| 순이익 | -US$10.37m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.0097 |
| 총이익률 | 52.14% |
| 순이익률 | -17.69% |
| 부채/자본 비율 | -146.3% |
STX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/13 12:54 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Shield Therapeutics plc는 10명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Howard Miller | Canaccord Genuity |
| Mark Brewer | Cavendish |
| Michael Mitchell | Cavendish |